We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month's issue covers relevant news from December 2019, including:
- The Solicitor General, on behalf of the US, asserts that the Supreme Court's Section 101 precedent creates "substantial uncertainty" requiring clarification
- The Federal Circuit holds that there is no single entity requirement for infringement under section 271(g)
- A district court holds that, under certain circumstances, an anticipatory reference is not necessarily "but-for" material under an inequitable conduct analysis
Download: The Bio/Pharma Beat - January 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
